CN107108640A - 布鲁顿酪氨酸激酶抑制剂的合成 - Google Patents

布鲁顿酪氨酸激酶抑制剂的合成 Download PDF

Info

Publication number
CN107108640A
CN107108640A CN201680005456.4A CN201680005456A CN107108640A CN 107108640 A CN107108640 A CN 107108640A CN 201680005456 A CN201680005456 A CN 201680005456A CN 107108640 A CN107108640 A CN 107108640A
Authority
CN
China
Prior art keywords
compound
formula
buddhist nun
shandong
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680005456.4A
Other languages
English (en)
Chinese (zh)
Inventor
西里尔·本海姆
陈伟
艾瑞克·戈德曼
A·霍尔瓦思
菲利普·派伊
马克·S·斯麦思
埃里克·J·弗纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Pharmacyclics LLC
Original Assignee
Janssen Pharmaceutica NV
Pharmacyclics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV, Pharmacyclics LLC filed Critical Janssen Pharmaceutica NV
Priority to CN202110485400.6A priority Critical patent/CN113816962A/zh
Publication of CN107108640A publication Critical patent/CN107108640A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201680005456.4A 2015-01-14 2016-01-14 布鲁顿酪氨酸激酶抑制剂的合成 Pending CN107108640A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110485400.6A CN113816962A (zh) 2015-01-14 2016-01-14 布鲁顿酪氨酸激酶抑制剂的合成

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562103507P 2015-01-14 2015-01-14
US62/103,507 2015-01-14
PCT/US2016/013424 WO2016115356A1 (en) 2015-01-14 2016-01-14 Synthesis of a bruton's tyrosine kinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110485400.6A Division CN113816962A (zh) 2015-01-14 2016-01-14 布鲁顿酪氨酸激酶抑制剂的合成

Publications (1)

Publication Number Publication Date
CN107108640A true CN107108640A (zh) 2017-08-29

Family

ID=56406389

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680005456.4A Pending CN107108640A (zh) 2015-01-14 2016-01-14 布鲁顿酪氨酸激酶抑制剂的合成
CN202110485400.6A Pending CN113816962A (zh) 2015-01-14 2016-01-14 布鲁顿酪氨酸激酶抑制剂的合成

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110485400.6A Pending CN113816962A (zh) 2015-01-14 2016-01-14 布鲁顿酪氨酸激酶抑制剂的合成

Country Status (16)

Country Link
US (6) US20180009814A1 (https=)
EP (1) EP3245208A4 (https=)
JP (2) JP2018502077A (https=)
KR (1) KR20170102887A (https=)
CN (2) CN107108640A (https=)
AU (2) AU2016206693A1 (https=)
BR (1) BR112017015206B1 (https=)
CA (2) CA3210320A1 (https=)
HK (1) HK1246293A1 (https=)
IL (4) IL322449A (https=)
MA (1) MA41350A (https=)
MX (2) MX394327B (https=)
RU (1) RU2017128308A (https=)
SG (2) SG10201906517VA (https=)
WO (1) WO2016115356A1 (https=)
ZA (1) ZA201704338B (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107814804A (zh) * 2017-10-27 2018-03-20 广州科锐特生物科技有限公司 依鲁替尼的制备方法
CN109988175A (zh) * 2019-04-28 2019-07-09 梯尔希（南京）药物研发有限公司 一种依鲁替尼-d5的制备方法
CN113874378A (zh) * 2019-05-21 2021-12-31 詹森药业有限公司 用于制备btk抑制剂的方法和中间体
CN113906011A (zh) * 2019-05-21 2022-01-07 詹森药业有限公司 用于制备btk抑制剂的方法和中间体
CN114853662A (zh) * 2021-02-05 2022-08-05 四川青木制药有限公司 手性肼基哌啶衍生物的制备方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6681922B2 (ja) * 2015-02-12 2020-04-15 上▲海▼度▲徳▼医▲藥▼科技有限公司 イブルチニブの製造方法
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
CN109206426B (zh) * 2017-07-06 2021-10-08 上海复星星泰医药科技有限公司 吡唑并嘧啶类化合物的制备方法
WO2019027860A1 (en) 2017-08-01 2019-02-07 Boehringer Ingelheim International Gmbh INTERMEDIATE COMPOUNDS AND METHODS
JP6918204B2 (ja) 2018-03-19 2021-08-11 大鵬薬品工業株式会社 アルキル硫酸ナトリウムを含む医薬組成物
KR20210044736A (ko) 2018-05-03 2021-04-23 주노 쎄러퓨티크스 인코퍼레이티드 키메라 항원 수용체(ｃａｒ) ｔ세포 요법과 키나제 억제제의 조합요법
JP6944496B2 (ja) * 2018-10-22 2021-10-06 ファイザー・インク ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
KR102742083B1 (ko) 2018-11-09 2024-12-16 다이호야쿠힌고교 가부시키가이샤 디메톡시벤젠 화합물의 제조 방법
US20240092785A1 (en) 2021-01-21 2024-03-21 Synthon B.V. Process for making ibrutinib
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101805341A (zh) * 2006-09-22 2010-08-18 药品循环公司 布鲁顿酪氨酸激酶的抑制剂
CN103319488A (zh) * 2007-03-28 2013-09-25 环状药物公司 布鲁顿氏酪氨酸激酶抑制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550214A (en) * 1981-01-05 1985-10-29 Polaroid Corporation Blocked vinyl biphenyl compounds
US4874822A (en) * 1988-04-07 1989-10-17 Minnesota Mining And Manufacturing Company Process for the acrylamidoacylation of alcohols
MXPA06007326A (es) * 2003-12-23 2007-01-26 Astex Therapeutics Ltd Derivados de pirazol como moduladores de proteina cinasa.
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
JP6261580B2 (ja) * 2012-07-30 2018-01-17 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化イブルチニブ
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN103626774B (zh) * 2013-11-20 2015-11-04 苏州明锐医药科技有限公司 伊鲁替尼的制备方法
CN105471823B (zh) * 2014-09-03 2018-10-26 阿里巴巴集团控股有限公司 一种敏感信息处理方法、装置、服务器及安全判定系统
US10266535B2 (en) * 2015-01-21 2019-04-23 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Inhibitor of FLT3 kinase and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101805341A (zh) * 2006-09-22 2010-08-18 药品循环公司 布鲁顿酪氨酸激酶的抑制剂
CN103319488A (zh) * 2007-03-28 2013-09-25 环状药物公司 布鲁顿氏酪氨酸激酶抑制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DISCLOSED ANONYMOUSLY: "A process for preparing (S)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one", 《IP.COM JOURNAL》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107814804A (zh) * 2017-10-27 2018-03-20 广州科锐特生物科技有限公司 依鲁替尼的制备方法
CN109988175A (zh) * 2019-04-28 2019-07-09 梯尔希（南京）药物研发有限公司 一种依鲁替尼-d5的制备方法
CN113874378A (zh) * 2019-05-21 2021-12-31 詹森药业有限公司 用于制备btk抑制剂的方法和中间体
CN113906011A (zh) * 2019-05-21 2022-01-07 詹森药业有限公司 用于制备btk抑制剂的方法和中间体
CN114853662A (zh) * 2021-02-05 2022-08-05 四川青木制药有限公司 手性肼基哌啶衍生物的制备方法
CN114853662B (zh) * 2021-02-05 2024-01-12 四川青木制药有限公司 手性肼基哌啶衍生物的制备方法

Also Published As

Publication number Publication date
RU2017128308A3 (https=) 2019-10-24
HK1246293A1 (zh) 2018-09-07
MX394327B (es) 2025-03-24
BR112017015206B1 (pt) 2023-04-11
US20220098200A1 (en) 2022-03-31
CN113816962A (zh) 2021-12-21
JP2018502077A (ja) 2018-01-25
SG11201705678YA (en) 2017-08-30
CA2971460A1 (en) 2016-07-21
IL322449A (en) 2025-09-01
JP2021035947A (ja) 2021-03-04
MA41350A (fr) 2017-11-21
WO2016115356A1 (en) 2016-07-21
ZA201704338B (en) 2023-10-25
IL274716A (en) 2020-07-30
BR112017015206A2 (pt) 2018-06-19
KR20170102887A (ko) 2017-09-12
US20180009814A1 (en) 2018-01-11
IL253020A0 (en) 2017-08-31
US20240158400A1 (en) 2024-05-16
SG10201906517VA (en) 2019-08-27
RU2017128308A (ru) 2019-02-14
MX366827B (es) 2019-07-25
IL308276A (en) 2024-01-01
CA2971460C (en) 2023-10-10
EP3245208A4 (en) 2018-10-17
US20250197404A1 (en) 2025-06-19
US20190367518A1 (en) 2019-12-05
AU2016206693A1 (en) 2017-07-13
CA3210320A1 (en) 2016-07-21
MX2019008815A (es) 2019-09-26
EP3245208A1 (en) 2017-11-22
AU2020230323A1 (en) 2020-10-01
US20200347064A1 (en) 2020-11-05
MX2017009154A (es) 2017-10-12

Similar Documents

Publication Publication Date Title
CN107108640A (zh) 布鲁顿酪氨酸激酶抑制剂的合成
TWI658042B (zh) 雜環化合物的合成
TWI454471B (zh) 製備細胞凋亡促進劑之方法
TWI735759B (zh) 細胞凋亡誘導劑之中間體及其製備方法
TWI710547B (zh) 抗病毒化合物之合成
KR101301200B1 (ko) 엔테카비르의 신규한 제조방법 및 이에 사용되는 중간체
CN110041333B (zh) 溴结构域抑制剂化合物及其用途
CN110698461A (zh) 第三代egfr抑制剂的制备方法
CN106661052A (zh) 头孢菌素衍生物的中间体及其制造方法
CN114591194A (zh) 一种对位官能团化芳胺化合物及其合成方法
CN116897149A (zh) 一种连接基药物偶联物的制备方法及其中间体
CN115361999A (zh) 2-[2-甲基氮杂环丁烷-1-基]-4-苯基-6-(三氟甲基)-嘧啶化合物
TWI784074B (zh) 用於製備苯并噻吩-2-基硼酸酯之方法
CN105753944A (zh) 达卡他韦及其衍生物的制备中间体
CA3187530A1 (en) Methods and intermediates for preparing jak inhibitors
WO2022032644A1 (zh) 一种取代的咪唑并[1,2-a]吡啶-2-基酰胺化合物的制备方法及其中间体
CN114057746B (zh) 作为tlr7激动剂的咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物的制备
BR122022026564B1 (pt) Processos para a preparação de 1-((r)-3-(4-amino-3-(4-fenoxifenil)-1hpirazol[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona (ibrutinibe) e compostos
CN109988172B (zh) 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
KR20200092945A (ko) 레날리도마이드의 결정형
JP2023179354A (ja) Ｈ－ホスホネート法を用いたモルフォリノ核酸の製造方法
TW202317140A (zh) 4-((r)-2-{[6-((s)-3-甲氧基-吡咯啶-1-基)-2-苯基-嘧啶-4-羰基]-胺基}-3-膦醯基-丙醯基)-哌-1-羧酸丁酯的合成方法
CN120344506A (zh) 新型氰基吡啶khk抑制剂化合物
JP2019196359A (ja) ピリミジン誘導体およびそれらの中間体を調製する化学的方法
WO2017162304A1 (en) Crystalline form

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170829